Taysha Gene Therapies (TSHA) Depreciation & Amortization (CF) (2020 - 2026)

Taysha Gene Therapies has disclosed Depreciation & Amortization (CF) across 7 years of filings, most recently posting $295000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $295000.0, up 4.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 4.12% YoY), and the FY2025 annual result was $1.1 million, down 8.33% from the prior year.
• Depreciation & Amortization (CF) came in at $295000.0 for Q1 2026 at Taysha Gene Therapies, down from $300000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q4 2022 to a low of $200000.0 in Q3 2025.
• The 5-year median for Depreciation & Amortization (CF) is $300000.0 (2022), against an average of $307764.7.
• Across the five-year window, Depreciation & Amortization (CF) soared 837.5% in 2022 and tumbled 34.43% in 2024, its largest moves.
• Taysha Gene Therapies' Depreciation & Amortization (CF) stood at $400000.0 in 2022, then dropped by 1.25% to $395000.0 in 2023, then slumped by 34.43% to $259000.0 in 2024, then gained by 15.83% to $300000.0 in 2025, then dropped by 1.67% to $295000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $295000.0 (Q1 2026), $300000.0 (Q4 2025), and $200000.0 (Q3 2025), per Business Quant data.